Aphaia Pharma
@aphaiapharma
Aphaia harnesses precision-targeted drug formulations to restore endogenous endocrine balance for the treatment and prevention of metabolic disorders.
ID: 1576939730578571264
https://aphaiapharma.com 03-10-2022 14:23:33
81 Tweet
86 Followers
92 Following
Our CSO Steffen-Sebastian Bolz, M.D., Ph.D., spoke with Pharma Technology Focus about patient recruitment for #obesity trials and Aphaia’s successful strategy for its Phase 2 trial through close relationships with CRO partners and medical centers. Read more here: brnw.ch/21wJvi6
Check out this Drug Discovery World article featuring insights from our CSO Steffen-Sebastian Bolz’s, M.D., Ph.D., from the panel he participated in at the 10th LSX World Congress on #cardiometabolic disease, #obesity and partnering opportunities for biotech: brnw.ch/21wJxqT
Learn about our approach & other innovative modalities in #obesity & cardiometabolic therapy beyond “hormone replacement” in this Scrip, Citeline Commercial article by Andrew McConaghie, capturing insights from our panel participation at the 10th LSX World Congress: bit.ly/3UYldgy
Check out this Endpoints News article featuring our CSO, Dr. Steffen-Sebastian Bolz, to learn more about the positive results from our Ph2 study evaluating our lead candidate for the treatment of #prediabetes to help prevent the progression to type 2 diabetes: bit.ly/3xqFRNk
Our CSO, Dr. Steffen-Sebastian Bolz, spoke with EmpoweredPatient on the #EmpoweredPatientPodcast about our ongoing Phase 2 trial in individuals with obesity, evaluating our lead drug in development, which is designed to restore metabolic balance. Listen here: bit.ly/4bkaVfJ
Our CSO, Steffen-Sebastian Bolz, MD, Ph.D., was featured on an episode of Xtalks Webinars Life Science Podcast, where he spoke about our innovative approach to treating metabolic conditions like #obesity and #prediabetes. Listen to the episode here: bit.ly/4g7c9OX